FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068263894> ?p ?o ?g. }

• W2068263894 endingPage "3460" @default.
• W2068263894 startingPage "3451" @default.
• W2068263894 abstract "The aim of this study was to investigate the potential protective role of fullerenol C60(OH)24 on doxorubicin-induced liver toxicity using in vivo (female Sprague-Dawley rats) and in vitro (human hepatocellular carcinoma - HepG2; colorectal adenocarcinoma cell lines - Caco-2) approaches. The first (healthy control) and second (control with chemically induced mammary carcinomas) group received saline only. The third, fourth and fifth group (all with breast cancer) were injected (i.p.) with a single dose of doxorubicin (8mg/kg), doxorubicin/fullerenol (100mg/kg of fullerenol 30min before administration of 8mg/kg doxorubicin) and fullerenol (100mg/kg), respectively. Two days after treatment, the rats were sacrificed. Results showed that treatment with doxorubicin alone caused significant changes in the serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and alpha-hydroxybutyrate dehydrogenase (alpha-HBDH), as well as in the levels of malondialdehyde (MDA), glutathione (GSH), glutathione peroxidase (GSH-Px), total antioxidant status (TAS), glutathione reductase (GR), catalase (CAT) and superoxide dismutase (SOD) in the liver tissue. These effects were significantly reduced for all investigated parameters by pre-treatment with fullerenol but not for the MDA and GSH level. The HepG2 and Caco-2 cell lines were continuously treated with fullerenol for 12h, 24h, 48h and 96h at concentrations of 10microg/mL and 44microg/mL. With the aim of evaluating the modulating activity of fullerenol on doxorubicin-induced hepatotoxicity, the cell lines were simultaneously treated with doxorubicin (1microm; 5microm) and fullerenol (10microg/mL; 44microg/mL) in different combinations. When the cells are treated with 5microm doxorubicin along with the fullerenol, we can see a significant improvement of the cell capability during the entire time-line. We can conclude that fullerenol has cytotoxic effects on HepG2 by itself, but when the oxidative stress is too high the cytotoxic effects of fullerenol are overcome by its protective role as a strong antioxidant compound." @default.
• W2068263894 created "2016-06-24" @default.
• W2068263894 creator A5001464347 @default.
• W2068263894 creator A5020499074 @default.
• W2068263894 creator A5051539953 @default.
• W2068263894 creator A5071586144 @default.
• W2068263894 creator A5074107180 @default.
• W2068263894 creator A5086417927 @default.
• W2068263894 creator A5088362346 @default.
• W2068263894 creator A5088366094 @default.
• W2068263894 date "2008-08-01" @default.
• W2068263894 modified "2023-10-12" @default.
• W2068263894 title "Potential hepatoprotective effects of fullerenol C60(OH)24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas" @default.
• W2068263894 cites W1591504141 @default.
• W2068263894 cites W1838909952 @default.
• W2068263894 cites W191793640 @default.
• W2068263894 cites W1963611166 @default.
• W2068263894 cites W1966704736 @default.
• W2068263894 cites W1970393724 @default.
• W2068263894 cites W1971076992 @default.
• W2068263894 cites W1971496138 @default.
• W2068263894 cites W1972502627 @default.
• W2068263894 cites W1975793229 @default.
• W2068263894 cites W1987593270 @default.
• W2068263894 cites W1988875770 @default.
• W2068263894 cites W1990452038 @default.
• W2068263894 cites W1997601568 @default.
• W2068263894 cites W2000568151 @default.
• W2068263894 cites W2003907808 @default.
• W2068263894 cites W2004421109 @default.
• W2068263894 cites W2004644030 @default.
• W2068263894 cites W2005382895 @default.
• W2068263894 cites W2007991039 @default.
• W2068263894 cites W2009819296 @default.
• W2068263894 cites W2023197012 @default.
• W2068263894 cites W2024029171 @default.
• W2068263894 cites W2026785305 @default.
• W2068263894 cites W2038851742 @default.
• W2068263894 cites W2039119111 @default.
• W2068263894 cites W2042714132 @default.
• W2068263894 cites W2045597377 @default.
• W2068263894 cites W2051998989 @default.
• W2068263894 cites W2056193077 @default.
• W2068263894 cites W2056842005 @default.
• W2068263894 cites W2057192944 @default.
• W2068263894 cites W2066996874 @default.
• W2068263894 cites W2071407201 @default.
• W2068263894 cites W2086810148 @default.
• W2068263894 cites W2090688263 @default.
• W2068263894 cites W2102122862 @default.
• W2068263894 cites W2107553772 @default.
• W2068263894 cites W2110230017 @default.
• W2068263894 cites W2143495872 @default.
• W2068263894 cites W2164705023 @default.
• W2068263894 cites W2220953335 @default.
• W2068263894 cites W4238481905 @default.
• W2068263894 cites W4240160695 @default.
• W2068263894 doi "https://doi.org/10.1016/j.biomaterials.2008.04.048" @default.
• W2068263894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18501960" @default.
• W2068263894 hasPublicationYear "2008" @default.
• W2068263894 type Work @default.
• W2068263894 sameAs 2068263894 @default.
• W2068263894 citedByCount "145" @default.
• W2068263894 countsByYear W20682638942012 @default.
• W2068263894 countsByYear W20682638942013 @default.
• W2068263894 countsByYear W20682638942014 @default.
• W2068263894 countsByYear W20682638942015 @default.
• W2068263894 countsByYear W20682638942016 @default.
• W2068263894 countsByYear W20682638942017 @default.
• W2068263894 countsByYear W20682638942018 @default.
• W2068263894 countsByYear W20682638942019 @default.
• W2068263894 countsByYear W20682638942020 @default.
• W2068263894 countsByYear W20682638942021 @default.
• W2068263894 countsByYear W20682638942022 @default.
• W2068263894 countsByYear W20682638942023 @default.
• W2068263894 crossrefType "journal-article" @default.
• W2068263894 hasAuthorship W2068263894A5001464347 @default.
• W2068263894 hasAuthorship W2068263894A5020499074 @default.
• W2068263894 hasAuthorship W2068263894A5051539953 @default.
• W2068263894 hasAuthorship W2068263894A5071586144 @default.
• W2068263894 hasAuthorship W2068263894A5074107180 @default.
• W2068263894 hasAuthorship W2068263894A5086417927 @default.
• W2068263894 hasAuthorship W2068263894A5088362346 @default.
• W2068263894 hasAuthorship W2068263894A5088366094 @default.
• W2068263894 hasConcept C126322002 @default.
• W2068263894 hasConcept C165069038 @default.
• W2068263894 hasConcept C181199279 @default.
• W2068263894 hasConcept C185592680 @default.
• W2068263894 hasConcept C2775838275 @default.
• W2068263894 hasConcept C2776151105 @default.
• W2068263894 hasConcept C2776694085 @default.
• W2068263894 hasConcept C2777318727 @default.
• W2068263894 hasConcept C2778401633 @default.
• W2068263894 hasConcept C2778760513 @default.
• W2068263894 hasConcept C2778979269 @default.
• W2068263894 hasConcept C2781303535 @default.
• W2068263894 hasConcept C538909803 @default.
• W2068263894 hasConcept C55493867 @default.

• next